… of BCR-ABL + cell lines to imatinib and nilotinib results in … BCR-ABL point mutations
causing resistance to imatinib in … , the combination of imatinib and nilotinib is highly efficacious …

… In chronic myeloid leukemia (CML), the major breakthrough has occurred with the introduction
of imatinib (Gleevec), a small-molecule inhibitor of BCR-ABL, the constitutively active …

… of the potentially differing effects of the 3 BCR/ABL-inhibitors approved for CML treatment
is available. To study the direct effects of Imatinib, Nilotinib and Dasatinib on NK cell reactivity, …

… crisis were lower with nilotinib than imatinib in patients with emergent BCR-ABL mutations.
… Nilotinib has in vitro inhibitory activity against all tested imatinib-resistant mutants of BCR-ABL…

… in the nilotinib group were lower than those in imatinib group. It indicated that nilotinib can
… In addition, the authors also found that nilotinib improved peripheral blood neutrophils and …

… The cognate target of imatinib, BCR-ABL, for which we observed peptides mapping to
both the BCR-part, as well as to the ABL-part, was identified as the major imatinib interactor. …

… of the activity of nilotinib in imatinib-resistant CML. We found that nilotinib has activity in
imatinib-… with mutations in the gene that encodes the ABL kinase that cause imatinib resistance. …

… Abl … nilotinib; Figure 1E), a high-affinity aminopyrimidine-based ATP-competitive inhibitor
that decreases proliferation and viability of wild-type BCR-ABL- and imatinib-resistant BCR-ABL …

… Our findings regarding nilotinib differ from results of these studies of imatinib in several
important respects. First, nilotinib is a more potent and selective BCR-ABL inhibitor than imatinib. …

… , it acts through competitive inhibition of the ATP binding site of BCR-ABL. In vitro nilotinib is
30 times more potent than imatinib against imatinib-sensitive cell lines and 3 to 7 times more …